Stock Track | Teva Pharmaceutical Plunges Over 7% in Pre-market Trading on Disappointing Q4 Results and Weak 2025 Outlook

Stock Track

Jan 29, 2025

Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.

The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.

Furthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1115983070"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115983070\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115983070?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115983070","market":"us","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Plunges Over 7% in Pre-market Trading on Disappointing Q4 Results and Weak 2025 Outlook","media":"Stock Track","content":"<p>Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.</p>\n\n<p>The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.</p>\n\n<p>Furthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Plunges Over 7% in Pre-market Trading on Disappointing Q4 Results and Weak 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Plunges Over 7% in Pre-market Trading on Disappointing Q4 Results and Weak 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-29 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.</p>\n\n<p>The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.</p>\n\n<p>Furthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1115983070","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115983070","pubTimestamp":1738154662,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical  stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 bill","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"由于第四季度业绩令人失望和2025年前景疲软，梯瓦制药(Teva Pharmaceutical)在盘前交易中暴跌超过7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.\nThe drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.\nFurthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}